These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1290382)

  • 1. [Thrombosis and thrombin].
    Hemker HC; Béguin S
    Ann Pharm Fr; 1992; 50(3):121-35. PubMed ID: 1290382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
    Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N
    Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
    Himber J; Kirchhofer D; Riederer M; Tschopp TB; Steiner B; Roux SP
    Thromb Haemost; 1997 Sep; 78(3):1142-9. PubMed ID: 9308768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-Xa molecules].
    Boneu B
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1491-4. PubMed ID: 9092408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mode of action of heparin and related drugs.
    Hemker HC; Beguin S
    Semin Thromb Hemost; 1991; 17 Suppl 1():29-34. PubMed ID: 1648791
    [No Abstract]   [Full Text] [Related]  

  • 15. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins].
    López-Sendón J; López de Sá E; Rubio Sanz R; Delcán Domínguez JL
    Rev Esp Cardiol; 1999; 52 Suppl 1():76-89. PubMed ID: 10364817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The Choay domain -- the structure responsible for the anticoagulant action of heparins].
    Hemker HC; al Dieri R; Wagenvoord R; Béguin S
    Bull Acad Natl Med; 2003; 187(1):59-66; discussion 66-7. PubMed ID: 14556454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SR123781A, a synthetic heparin mimetic.
    Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
    Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
    Fiore MM; Mackie IM
    Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New anticoagulants.
    Bauer KA
    Curr Opin Hematol; 2008 Sep; 15(5):509-15. PubMed ID: 18695376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.